BEACOPP is
a chemotherapy regimen for treatment of Hodgkin lymphoma developed by the German Hodgkin Study Group used for patients in Stages > II or early with unfavorable risk factors. Patients typically
receive treatment in cycles of 21 days with no drugs given on days 15–21.
